Therapeutic options for regionally advanced non-small cell lung cancer

被引:14
作者
Buccheri, G [1 ]
Ferrigno, D [1 ]
机构
[1] A CARLE HOSP CHEST DIS,I-12100 CUNEO,ITALY
关键词
non-small cell lung cancer; locally advanced disease; chemotherapy; radiotherapy; surgery;
D O I
10.1016/0169-5002(96)00554-5
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The optimal treatment for regionally advanced non-small cell lung cancer (NSCLC, Stage IIIa/IIIb) remains unknown. Proposed approaches include surgery, radiotherapy, chemotherapy, and combinations of these. No treatment modality, however, has ever shown other than modest or minimal beneficial effects. When differences between new and old treatments appear trivial, as in the management of the locally advanced NSCLC, controlled studies are necessary to select the best approach. This review is based on a systematic overview of data from randomized trials comparing different treatment modalities. The following six points emerged from the cited literature. (1) It is sufficiently proved that chemotherapy alone prolongs survival in patients with both locally advanced and metastatic disease. (2) Although it is probably true that radiation therapy is better than no active treatment, this idea is supported by very limited evidence. (3) Although it is probably also true that radiotherapy alone is not worse than chemotherapy alone, this is another insufficiently proved issue. (4) The possible superiority of chemo-radiotherapy to chemotherapy alone or to supportive care is also poorly documented. (5) There is abundant evidence that chemo-radiotherapy is better than radiotherapy alone (however, this information may be unhelpful if point 2, or 3 remains unclarified). (6) Although neoadjuvant treatments have improved resectability and may ensure overall better results, the surgical cure, either alone or in combination with chemotherapy or chemo-radiotherapy, is another unproved option. Based on the above six points, it was concluded that new randomized studies are urgently needed to confirm the possible superiority of chemo-radiotherapy to chemotherapy. Only after such a validation, will the many ongoing trials, designed to prove the possible superiority of local surgical control to the more traditional approaches based on thoracic irradiation, have a practical sense.
引用
收藏
页码:281 / 300
页数:20
相关论文
共 50 条
  • [41] Gefitinib in advanced non-small cell lung cancer
    Sharma, R
    Boyer, M
    Clarke, S
    Millward, M
    INTERNAL MEDICINE JOURNAL, 2005, 35 (02) : 77 - 82
  • [42] The treatment of advanced non-small cell lung cancer
    Spiro, SG
    Silvestri, GA
    CURRENT OPINION IN PULMONARY MEDICINE, 2005, 11 (04) : 287 - 291
  • [43] Comparison between immunotherapy efficacy in early non-small cell lung cancer and advanced non-small cell lung cancer: a systematic review
    Wang, Yimin
    Li, Chuling
    Wang, Zimu
    Wang, Zhaofeng
    Wu, Ranpu
    Wu, Ying
    Song, Yong
    Liu, Hongbing
    BMC MEDICINE, 2022, 20 (01)
  • [44] Current and novel therapeutic strategies for optimizing immunotherapy outcomes in advanced non-small cell lung cancer
    Martin, Claudio
    Enrico, Diego
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [45] Tumor Vasculature as a Therapeutic Target in Non-small Cell Lung Cancer
    Bar, Jair
    Goss, Glenwood D.
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (03) : 609 - 620
  • [46] Pharmacotherapeutic options for treating brain metastases in non-small cell lung cancer
    Metro, Giulio
    Chiari, Rita
    Ricciuti, Biagio
    Rebonato, Alberto
    Lupattelli, Marco
    Gori, Stefania
    Bennati, Chiara
    Castrioto, Corrado
    Floridi, Piero
    Minotti, Vincenzo
    Chiarini, Pietro
    Crino, Lucio
    EXPERT OPINION ON PHARMACOTHERAPY, 2015, 16 (17) : 2601 - 2613
  • [47] Therapeutic Strategy for Treatment of Metastatic Non-Small Cell Lung Cancer
    Berhoune, Malik
    Banu, Eugeniu
    Scotte, Florian
    Prognon, Patrice
    Oudard, Stephane
    Bonan, Brigitte
    ANNALS OF PHARMACOTHERAPY, 2008, 42 (11) : 1640 - 1652
  • [48] Current immune therapeutic strategies in advanced or metastatic non-small cell lung cancer
    Xu Jing
    Liu Caixia
    Wu Xiaonan
    Ma Jie
    中华医学杂志英文版, 2023, 136 (15)
  • [49] CIMAvax-EGF: A New Therapeutic vaccine for Advanced Non-Small Cell Lung Cancer Patients
    Saavedra, Danay
    Crombet, Tania
    FRONTIERS IN IMMUNOLOGY, 2017, 8
  • [50] Treatment of locally advanced non-small cell lung cancer with combination of chemotherapy and radiation
    Martins, RG
    SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE, 2005, 26 (03) : 273 - 277